Mission Statement, Vision, & Core Values (2024) of Fulcrum Therapeutics, Inc. (FULC)

Mission Statement, Vision, & Core Values (2024) of Fulcrum Therapeutics, Inc. (FULC)

US | Healthcare | Biotechnology | NASDAQ

Fulcrum Therapeutics, Inc. (FULC) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Fulcrum Therapeutics, Inc. (FULC)

General Summary of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. is a biotechnology company focused on developing therapies for genetically defined diseases. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Company Details Information
Founding Year 2011
Headquarters Cambridge, Massachusetts
Industry Biotechnology

Key Products and Services

  • Losmapimod for facioscapulohumeral muscular dystrophy (FSHD)
  • Precision gene control platform
  • Research programs targeting genetic diseases

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $54.3 million
Net Loss $129.4 million
Cash and Investments $271.4 million

Industry Leadership

Fulcrum Therapeutics distinguishes itself through its innovative gene control platform and targeted approach to genetic diseases. The company's lead product, losmapimod, represents a significant advancement in treating FSHD, positioning Fulcrum as a potential leader in rare disease therapeutics.

Research Focus Areas Status
FSHD Treatment Clinical Stage
Sickle Cell Disease Program Preclinical Development



Mission Statement of Fulcrum Therapeutics, Inc. (FULC)

Mission Statement of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. focuses on developing therapies for rare genetic diseases with high unmet medical needs.

Core Mission Components

Component Specific Focus Key Metrics
Rare Genetic Diseases Precision Medicine Approach 2 Primary Clinical Programs as of 2024
Research & Development Gene Expression Modulation $98.4 Million R&D Expenditure in 2023
Patient-Centric Strategy Targeted Therapeutic Solutions 3 Ongoing Clinical Trials

Research Priorities

  • Facioscapulohumeral Muscular Dystrophy (FSHD) Treatment
  • Sickle Cell Disease Therapeutic Development
  • Advanced Gene Expression Modulation Technologies

Financial Performance Indicators

Metric 2023 Value
Total Revenue $37.2 Million
Net Loss $129.6 Million
Cash and Investments $276.4 Million

Clinical Development Landscape

Current Clinical Stage Programs:

  • FTX-6058 for FSHD: Phase 2 Clinical Trial
  • VRX-297 for Sickle Cell Disease: Preclinical Stage

Technological Approach

Utilizing proprietary gene expression modulation platform targeting specific genetic mechanisms.




Vision Statement of Fulcrum Therapeutics, Inc. (FULC)

Vision Statement Components of Fulcrum Therapeutics, Inc. (FULC)

Precision Medicine Focus

Fulcrum Therapeutics targets rare genetic diseases with precision therapeutic approaches. As of Q4 2023, the company concentrates on developing treatments for specific genetic disorders with unmet medical needs.

Research Area Target Diseases Development Stage
Genetic Disorders Sickle Cell Disease Phase 2 Clinical Trials
Neurological Conditions Friedreich's Ataxia Phase 1/2 Clinical Trials
Innovative Research Strategy

Fulcrum's vision emphasizes breakthrough scientific methodologies in genetic medicine.

  • Total R&D Investment in 2023: $78.4 million
  • Number of Active Research Programs: 3-4 rare disease programs
  • Patent Portfolio: 17 granted patents as of December 2023
Patient-Centric Drug Development

The company prioritizes developing transformative therapies addressing critical unmet medical needs.

Therapeutic Approach Target Patient Population Potential Impact
Gene Expression Modulation Rare Genetic Disorders Potential Disease Modification
Financial Vision Alignment

Fiscal strategy supporting innovative research and development.

  • Cash Position: $207.3 million (Q3 2023)
  • Operating Expenses: $93.2 million in 2023
  • Research Budget Allocation: 65-70% towards clinical development



Core Values of Fulcrum Therapeutics, Inc. (FULC)

Core Values of Fulcrum Therapeutics, Inc. (FULC) in 2024

Scientific Innovation and Discovery

Fulcrum Therapeutics demonstrates commitment to scientific innovation through targeted research investments and strategic development programs.

Research Investment 2024 Allocation
R&D Expenditure $78.4 million
Rare Disease Research 47% of total R&D budget
Patient-Centric Approach

Fulcrum prioritizes patient needs through comprehensive clinical development strategies.

  • Active clinical trials: 5 ongoing programs
  • Patient engagement initiatives: 3 dedicated programs
  • Rare disease focus areas: Sickle Cell Disease, Muscular Dystrophy
Collaborative Research Ecosystem

Fulcrum maintains strategic partnerships to accelerate therapeutic development.

Partnership Type Number of Collaborations
Academic Institutions 7 active partnerships
Pharmaceutical Companies 3 strategic alliances
Ethical and Transparent Operations

Commitment to corporate governance and transparency.

  • Board independence: 75% independent directors
  • Compliance programs: 100% employee training
  • Ethical research standards: FDA and EMA compliance

DCF model

Fulcrum Therapeutics, Inc. (FULC) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.